Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.42 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ME3 | Q16798 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17746117 | 0.85 | TDP1 (0.55) | GPR119USP2ME3TDP1 | |
| SCHEMBL2555420 | 0.84 | AKR1C3 (0.65) | AKR1C3USP2ME3TDP1SMN1; SMN2 | |
| SCHEMBL13506522 | 0.84 | USP2 (0.64) | GPR119AKR1C3USP2MBTD1TP53BP1 | |
| SCHEMBL3486877 | 0.84 | GFER (0.53) | GPR119AKR1C3USP2MBTD1TP53BP1 | |
| SCHEMBL3485750 | 0.81 | GPR119 (0.47) | GPR119AKR1C3USP2MBTD1TP53BP1 | |
| SCHEMBL4555361 | 0.81 | GPR119 (0.66) | GPR119USP2MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL3486788 | 0.81 | TRIM24 (0.53) | GPR119SMN1; SMN2 | |
| SCHEMBL3486611 | 0.80 | GPR119 (0.68) | GPR119AKR1C3USP2MBTD1TP53BP1 | |
| SCHEMBL3487510 | 0.80 | KDM4E (0.47) | GPR119 | |
| SCHEMBL10316360 | 0.80 | ITGB3 (0.52) | GPR119ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8399485-B2 | Acyl bipiperidinyl compounds useful as GPR 119 agonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| EP-2121661-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| EP-2112880-A2 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2009-11-04 | — | — | EP | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008076243-A2 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075987-A1 | ACYL BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR27, FFAR2 | GPR119 1/4885AKR1C3 1257/4885USP2 3281/4885 |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885AKR1C3 1412/4885USP2 3472/4885 |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885AKR1C3 1595/4885USP2 3372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.